Detail of "14321-27-8"

Reference

Synthesis and characterization of the firstly observed two brilliantly triboluminescent lanthanide complexes: 2-hydroxyethylammonium and pyrrolidinium tetrakis(dibenzoylmethanide)europate(III)

Synthesis and characterization of the firstly observed two brilliantly triboluminescent lanthanide complexes: 2-hydroxyethylammonium and pyrrolidinium tetrakis(dibenzoylmethanide)europate(III). Crystal structure of one brilliantly triboluminescent acentric complex: dimethylbenzylammonium tetrakis(dibenzoylmethanide)europate. Xiong, Ren-Gen; You, Xiao-Zeng (The State Key Laboratory of Coordination Chemistry, Coordination Chemistry Institute, Nanjing University, Nanjing 210093, Peop. Rep. China). Inorganic Chemistry Communications, 5(9), 677-681 (English) 2002 Elsevier Science B.V. CODEN: ICCOFP. ISSN: 1387-7003. DOCUMENT TYPE: Journal CA Section: 78 (Inorganic Chemicals and Reactions) Section cross-reference(s): 73, 75 Triboluminescent phenomena of 2-hydroxyethylammonium tetrakis(dibenzoylmethanide)europate (1) and pyrrolidonium tetrakis(dibenzoylmethanide)europate (2) were firstly obsd., and the crystal structure of dimethylbenzylammonium tetrakis(dibenzoylmethanide)europate (3) was successfully detd. after >35 yr later. Crystal data for 3: orthorhombic, space group Pca21, a 25.697(2), b 9.462(3), c 15.023(3) A, Z = 4. The Eu atom exhibits an eight-coordinate tetragonal antiprismatic geometry with an av. Eu-O bond distance of 2. 14321-27-8 and 616-45-5 which are cas registry numbers of substances are two of reagents here.42(2) ?. Triboluminescent spectra of 1-3 are basically similar to that of their fluorescent spectra, and the obsd. triboluminescent emission correlates well with their acentric space group. .

Preparation of benzamide derivatives as hydroxysteroid dehydrogenase modulators

Powers, Jay P.; Degraffenreid, Michael R.; He, Xiao; Julian, Lisa; McMinn, Dustin L.; Sun, Daqing; Rew, Yosup; Yan, Xuelei (Amgen Inc., USA). PCT Int. Appl. WO 2006138508 A2 28 Dec 2006, 161pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). (World Intellectual Property Organization).Several reagents with their cas registry numbers 917769-61-0 and 14321-27-8 are used here. CODEN: PIXXD2. APPLICATION: WO 2006-US23395 15 Jun 2006. PRIORITY: US 2005-691244P 17 Jun 2005. DOCUMENT TYPE: Patent CA Section: 25 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds) Section cross-reference(s): 1, 2, 63 Title compds. I [R1 = OH, halo, haloalkyl; R2 and R3 independently = halo, alkyl, alkenyl, alkynyl, etc., wherein no more than two of R1-3 are halo; R4 = H, halo, alkyl, and cycloalkyl; R5 = halo, CN, NO2, etc.; R6 = halo, CN, NO2, Me, Et, etc.], and their pharmaceutically acceptable salts, are prepd. and disclosed as hydroxysteroid dehydrogenase modulators having therapeutic utility, particularly in the treatment of diabetes, obesity and related conditions and disorders. Thus, e.g., II was prepd. by amidation of 4-(1,1,1-trifluoro-2-hydroxypropan-2-yl)benzoic acid (prepn. given) with N-methylbenzylamine. In assays of in vitro 11b-HSD1 activity, I demonstrated IC50 values of 1000 nM to < 1 nM. .